Business Wire

Technology Innovation Institute’s Secure Systems Research Centre Partners with Purdue University on Game-Changing UAV Security Project

10.3.2021 13:29:00 EET | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Purdue University, a world-renowned US-based public research university. The two entities are collaborating on a three-year sophisticated cybersecurity project to ensure Unmanned Aerial Vehicles (UAVs) can be used safely and efficiently in urban operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005409/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) - (Photo: AETOSWire)

Secure Systems Research Centre is one of initial seven dedicated research centres at TII. The research collaboration with Purdue University, titled ‘Cybersecurity for UAS Operations in Urban Environment’, includes the study of security and resilience in cyber-physical and autonomous systems. The project examines safety challenges that Unmanned Aerial Systems (UASs) experience in operating environments. These systems and vehicles are vulnerable to sophisticated cyberattacks in terms of communication, navigation, surveillance, and command and control. The outcome of this research will help other research at Secure Systems Research Centre in the future.

Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is becoming increasingly complex. This is evidenced by the rising number of cyberattacks and surveillance breaches that occur daily. We must regain control over critical digital systems. We are optimistic that the research outcomes at TII’s Secure Systems Research Centre will allow us to gain the upper hand in the fight against these malicious attacks.”

He added: “We are delighted to have the Purdue Team led by Prof. Inseok Hwang of School of Aeronautics and Astronautics partner on making cyber-physical and autonomous systems secure and resilient to malware using their state of the art autonomous drone testing facility. This will enable commercial autonomous drones and robots growth in the UAE and worldwide, opening new opportunities to enterprises and making their use safer for all people.”

A multidisciplinary group of researchers from Purdue University will join forces with TII’s Secure Systems Research Centre team.

The research project comprises four phases of development. First, it will carry out a modelling and analysis of UAS security. Second, it will develop algorithms and methodologies for high-assurance autonomy. Third, it will construct an experimental environment and work to simulate safe and secure urban UAS operations. Finally, it will test and validate mitigation strategies in a scaled, mixed-reality testbed.

This three-year project is led by Prof. Inseok Hwang as the principal investigator. Prof. Hwang is assisted on this project by two co-researchers from Purdue University – Prof. James Goppert, a visiting assistant professor at the School of Aeronautics and Astronautics and managing director of the UAS Research and Test Facility; and Prof. Dongyan Xu, the Samuel D. Conte Professor of Computer Science and Director of CERIAS (Center for Education and Research in Information Assurance and Security), Purdue’s cybersecurity research and education center.

Prof. Hwang will assess potential cyberattacks on the systems, Prof. Xu will conduct resource-efficient encryption, multi-UAS communications, and other research from the cyber perspective while Prof. Goppert will test the drones in a special mixed reality environment he will design and build.

Prof. Hwang said: “This landmark project comes at a time of growing reliance on UASs across various sectors – from security to medicine and logistics, and everything in between. We are confident that our partnership will translate into global wins for the international community and lead to many more research milestones in the years to come.”

For more information, please visit www.tii.ae and https://securesystems.tii.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye